Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities
Authors:
Open Access
- 25 April 2024
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116615
Abstract
No abstract availableKeywords
This publication has 143 references indexed in Scilit:
- The Relevance of Notch Signaling in Cancer Progression2020
- Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancerBreast Cancer Research and Treatment, 2020
- Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trialBreast Cancer Research and Treatment, 2020
- GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patientsArchives of Gynecology and Obstetrics, 2020
- IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancerInternational Journal of Cancer, 2019
- G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifenBreast Cancer Research and Treatment, 2018
- The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrenceBreast Cancer Research and Treatment, 2018
- GPER, IGF‐IR, and EGFR transduction signaling are involved in stimulatory effects of zinc in breast cancer cells and cancer‐associated fibroblastsMolecular Carcinogenesis, 2016
- Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growthBreast Cancer Research and Treatment, 2005
- Identification of a Gene (GPR30) with Homology to the G-Protein-Coupled Receptor Superfamily Associated with Estrogen Receptor Expression in Breast CancerGenomics, 1997